Archive for September 26, 2011

Are all beta-lactams similarly effective in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia?

Clinical Microbiology and Infection October 2011 V.17 N.10 P.1581-1586

M. Paul1,2, N. Zemer-Wassercug1, O. Talker1, Y. Lishtzinsky1, B. Lev3, Z. Samra2,3, L. Leibovici2,4, J. Bishara1,2

1-Unit of Infectious Diseases, Rabin Medical Center, Beilinson Hospital, Petah-Tikva, Israel

2-Sacker Faculty of Medicine, Tel-Aviv University, Ramat-Aviv, Israel

3-Microbiology Laboratory Rabin Medical Center, Beilinson Hospital, Petah-Tikva, Israel

4-Medicine E, Rabin Medical Center, Beilinson Hospital, Petah-Tikva, Israel

*Correspondence: Corresponding author: M. Paul, Infectious Diseases Unit, Rabin Medical Center, Beilinson Hospital, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel E-mail:


Methicillin-sensitive Staphylococcus aureus (MSSA) is susceptible to many beta-lactams. We compared cloxacillin and cefazolin, the first-line recommended antibiotics, and other beta-lactams in the treatment of MSSA bacteraemia. This was a retrospective cohort study. Included were adult patients with clinically-significant MSSA bacteraemia treated with a beta-lactam that was started within 48 h after blood cultures were taken. We separated between empirical treatment administered to the patient before receipt of final blood culture results and definitive treatment administered thereafter. Univariate and multivariable analyses for 30-day (empirical treatment) and 90-day (definitive treatment) mortality were conducted, including the type of beta-lactam administered to the patient. Five-hundred and forty-one patients were included for the analysis of empirical treatment and 498 patients alive at 7 days were evaluable for definitive treatment. Empirical treatment with cloxacillin or cefazolin (n = 131) was associated with lower 30-day mortality as compared with cefuroxime (n = 98, p 0.058), ceftriaxone or cefotaxime (n = 194, p 0.008) and beta-lactam-beta-lactamase combinations (n = 61, p 0.013), with adjusted odds ratios (OR) for death ranging from 1.98 to 2.68. Definitive treatment with cefazolin (n = 72) was not significantly different from cloxacillin (n = 281); adjusted OR for 90-day mortality 0.91 (95% confidence interval 0.47–1.77). Treatment with cefazolin both in the empirical and definitive periods was not significantly different from cloxacillin; adjusted OR 0.81 (95% confidence interval 0.18–3.62). Treatment of MSSA bacteraemia with cefazolin is not significantly different from treatment with cloxacillin, while treatment with other beta-lactams, including second and third generation cephalosporins, might be associated with higher mortality.


September 26, 2011 at 3:46 pm Leave a comment

Clonal dissemination of Klebsiella pneumoniae ST258 harbouring KPC-2 in Argentina

Clinical Microbiology and Infection October 2011 V.17 N.10 P.1520-1524


S. A. Gomez1,†, F. G. Pasteran1,‡, D. Faccone1, N. Tijet2, M. Rapoport1, C. Lucero1, O. Lastovetska2,3,4, E. Albornoz1, M. Galas1, KPC Group

1-Servicio Antimicrobianos, Instituto Nacional de Enfermedades Infecciosas (INEI)-ANLIS ‘Dr Carlos G. Malbrán;, Ciudad Autónoma de Buenos Aires, Argentina

2-Ontario Agency for Health Protection and Promotion, Public Health Laboratories

3-Department of Laboratory Medicine & Pathobiology, University of Toronto

4-Department of Microbiology, Mount Sinai Hospital, Toronto, ON, Canada

*Correspondence: Corresponding author: S. A. Gomez, Servicio Antimicrobianos, Instituto Nacional de Enfermedades Infecciosas (INEI)-ANLIS ‘Dr Carlos G. Malbrán’, Av. Velez Sarsfield 563, 1282AFF, Ciudad Autónoma de Buenos Aires, Argentina E-mail:


The present work describes the abrupt emergence of Klebsiella pneumoniae carbapenemase (KPC) and characterizes the first 79 KPC-producing enterobacteria fromArgentina(isolated from 2006 to 2010). The emergence of blaKPC-2 was characterized by two patterns of dispersion: the first was the sporadic occurrence in diverse enterobacteria from distant geographical regions, harbouring plasmids of different incompatibility groups and blaKPC-2 inan unusual genetic environment flanked by ISKpn8-ΔblaTEM-1 and ISKpn6-like. blaKPC-2 was associated with IncL/M transferable plasmids; the second was the abrupt clonal spread of K. pneumoniae ST258 harbouring blaKPC-2 inTn4401a.


September 26, 2011 at 3:44 pm Leave a comment

Fever in a returned traveler.

Cleve Clin J Med. 2005 Oct;72(10):921-7.

Lesho EP, George S, Wortmann G.

Walter Reed Army  Medical Center, Washington, DC, USA.


September 26, 2011 at 1:00 am Leave a comment

Fever in returned travelers: results from the GeoSentinel Surveillance Network.

Clin Infect Dis. 2007 Jun 15;44(12):1560-8.

Wilson ME, Weld LH, Boggild A, Keystone JS, Kain KC, von Sonnenburg F, Schwartz E; GeoSentinel Surveillance Network.

Mount Auburn Hospital, Cambridge, MA, USA.



Fever is a marker of potentially serious illness in returned travelers. Information about causes of fever, organized by geographic area and traveler characteristics, can facilitate timely, appropriate treatment and preventive measures.


Using a large, multicenter database, we assessed how frequently fever is cited as a chief reason for seeking medical care among ill returned travelers. We defined the causes of fever by place of exposure and traveler characteristics.


Of 24,920 returned travelers seen at a GeoSentinel clinic from March 1997 through March 2006, 6957 (28%) cited fever as a chief reason for seeking care. Of patients with fever, 26% were hospitalized (compared with 3% who did not have fever); 35% had a febrile systemic illness, 15% had a febrile diarrheal disease, and 14% had fever and a respiratory illness. Malaria was the most common specific etiologic diagnosis, found in 21% of ill returned travelers with fever. Causes of fever varied by region visited and by time of presentation after travel. Ill travelers who returned from sub-Saharan Africa, south-central Asia, and Latin  America whose reason for travel was visiting friends and relatives were more likely to experience fever than any other group. More than 17% of travelers with fever had a vaccine-preventable infection or falciparum malaria, which is preventable with chemoprophylaxis. Malaria accounted for 33% of the 12 deaths among febrile travelers.


Fever is common in ill returned travelers and often results in hospitalization. The time of presentation after travel provides important clues toward establishing a diagnosis. Preventing and promptly treating malaria, providing appropriate vaccines, and identifying ways to reach travelers whose purpose for travel is visiting friends and relatives in advance of travel can reduce the burden of travel-related illness.



September 26, 2011 at 12:56 am Leave a comment

Evaluating a sick child after travel to developing countries.

J Am Board Fam Med. 2010 Nov-Dec;23(6):704-13.

Tolle MA.

Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030,


Every year, millions of children travel internationally with their families, many to developing countries. Although the vast majority experience uneventful travel and return home well, it is not uncommon for children to present as ill during or after travel. Although the majority of travel-associated illness is mild and self-limited, serious conditions regularly occur. Almost all life-threatening conditions after travel present with fever, and malaria is the most important of these to rapidly exclude. Gastrointestinal symptoms are common after travel in the developing world, and most diarrhea in child travelers has a bacterial
source. Children who have a rash in association with fever or who appear ill should receive a priority work-up focused on ruling out serious conditions. Many children traveling internationally experience respiratory illness during or shortly after travel, mainly common upper respiratory infections, yet serious conditions, such as tuberculosis, may occur. Eosinophilia is common in the returned pediatric traveler, particularly those with prolonged stays in the tropics. Not all eosinophilia is caused by parasitic infection; drug reactions, asthma, and other allergic conditions are also common causes. With a focus first on ruling out life-threatening disease and subsequently on an informed and efficient path to diagnosis and treatment, clinicians may confidently
provide care for this challenging group of patients.



September 26, 2011 at 12:52 am Leave a comment

Rickettsia typhi infection with interstitial pneumonia in a traveler treated with moxifloxacin.

J Clin Microbiol. 2011 Feb;49(2):741-3.

Schulze MH, Keller C, Müller A, Ziegler U, Langen HJ, Hegasy G, Stich A.

Medical Mission Hospital, Department of Tropical Medicine, Salvatorstrasse 7, 97067 Würzburg, Germany.


Rickettsial diseases may play an important part in the differential diagnosis of fever in returned travelers. The initial empirical treatment needs to take Rickettsia species into consideration to avoid the development of life-threatening courses. Here, we
present a case of interstitial pneumonia associated with Rickettsia typhi infection treated with moxifloxacin.



September 26, 2011 at 12:47 am Leave a comment


September 2011

Posts by Month

Posts by Category